Asensus Surgical Inc (ASXC)

[la_trader]

that's one question that easily answers itself. ISRG had a monopoly. no need to spend big money on new tech when you can keep selling your captive market the same old robot and same old overpriced consumables, rinse / repeat, and milk it for everything possible. that $100m went into the exec pockets instead. to date ISRG has ignored urgent customer requests for things like haptic feedback, reusable tools, comfort for surgeon, and instead did some weak offering of a watered down old bot with a lower price point. that is hilarious. talk about giving your customers the big finger.

since Senhance was proven by FDA to be at least as effective as Davinci, eventually hospitals are going to go with the robot that has these requested features, lower TCI and AFAIK better purchase pricing / lease options.

combine that with all of the lawsuits building against ISRG and it is crazy to think that Senhance will not sell units.